PDS Biotechnology Corp (PDSB) — Cash Flow-to-Debt Ratio
PDS Biotechnology Corp (PDSB) has a Cash Flow-to-Debt Ratio of -210.47x as of March 2026, meaning its operating cash flow of $-4.37 Billion could theoretically repay -210% of its total liabilities ($20.77 Million) in one year. Check cash flow reinvestment rate of PDS Biotechnology Corp to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
PDS Biotechnology Corp Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for PDS Biotechnology Corp across 14 annual periods. Also explore how large is PDS Biotechnology Corp's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for PDS Biotechnology Corp (2012–2025)
Year-by-year debt coverage analysis for PDS Biotechnology Corp. For market capitalisation and broader financial context, see PDSB company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1306.45x | $-27.75 Billion | $21.24 Million | ▼ -98186.6% |
| 2024 | -1.33x | $-35.03 Million | $26.35 Million | ▼ -31.4% |
| 2023 | -1.01x | $-33.64 Million | $33.26 Million | ▼ -29.8% |
| 2022 | -0.78x | $-25.71 Million | $33.01 Million | ▲ +75.1% |
| 2021 | -3.13x | $-12.49 Million | $3.99 Million | ▲ +10.4% |
| 2020 | -3.50x | $-13.15 Million | $3.76 Million | ▲ +46.0% |
| 2019 | -6.47x | $-18.07 Million | $2.79 Million | ▼ -24.5% |
| 2018 | -5.19x | $-33.15 Million | $6.38 Million | ▼ -286.1% |
| 2017 | -1.35x | $-40.70 Million | $30.25 Million | ▲ +9.6% |
| 2016 | -1.49x | $-32.19 Million | $21.64 Million | ▲ +20.6% |
| 2015 | -1.87x | $-21.75 Million | $11.62 Million | ▼ -765.2% |
| 2014 | -0.22x | $-9.71 Million | $44.88 Million | ▲ +35.2% |
| 2013 | -0.33x | $-8.04 Million | $24.08 Million | ▲ +47.2% |
| 2012 | -0.63x | $-2.25 Million | $3.55 Million | — |